Log in Register
Menu

MCF7/TAMR-4 Cell Line

Invented by Dr Anne Lykkesfeldt at Danish Cancer Society

Info

Catalogue Number 152088
Antigen/Gene or Protein Targets Oestrogen receptor
Parental Line MCF7 S0.5
Host Human
Tissue Breast
Disease Keywords Breast cancer, tamoxifen-resistant
Model Tumour line
Relevance The MCF7/TAMR-4 Cell line is a breast cancer cell line resistant to tamoxifen. Tamoxifen is by far the most widely used drug for hormone-dependent breast cancer. However, primary or acquired resistance to Tamoxifen severely limits its clinical effectiveness. The MCF7/TAMR-4 cell line is a good model cell to study the signalling pathways which are the major drivers of tamoxifen-resistant growth.
Production Details The parental cell line for the MCF7/TAMR-4 cells is MCF7/S0.5, which was adapted to grow at low serum concentration in order to study the effect of estradiol and tamoxifen. MCF7/TAMR-4 has been established from a clone of cells that survived long term treatment with 1 µM tamoxifen. Tamoxifen-resistant cells are passaged continuously in presence of 1 µM tamoxifen, which is lethal for the parental MCF7/S0.5 cell line.
Research Area Cancer, Drug Discovery & Development
Recommended Growing Conditions 37°C under 5% CO2 in air using phenol red-free DMEM:Ham’s F-12 containing 1% fetal bovine serum, 2 mM Glutamax and 6 ng/ml insulin. To maintain high-level resistance, medium was supplemented with Tamoxifen (1 μM).
Positive Control MCF7-S0.5 (parental cell line)
Notes MCF7/TAMR-4 cells are oestrogen receptor positive and progesterone receptor negative. MCF7/TAMR-4 cells are growth inhibited by the pure antiestrogen fulvestrant. The oestrogen receptor is a major driver of growth of MCF7/TAMR-4 cell, ref 1. Treatment targeting the Aurora kinase A restores sensitivity to tamoxifen treatment.
The TAMR lines were established from the MCF7/S0.5 cell line, which was adapted to grow with 0.5% fetal calf serum in phenol red containing DMEM/F12 medium. Treatment with tamoxifen was started in passage 351. Few colonies of cells survived the treatment and after 28 days of tamoxifen treatment, tamoxifen was omitted from the medium for 22 days. After 19 passages without tamoxifen (passage 372) the cells underwent a second treatment with tamoxifen which initially reduced cell growth rate, but around 390-400 the growth rate of the tamoxifen resistant cell lines was close to the growth rate of the parental MCF7/S0.5 cells.

Passage 402 (AL3482), 403 (AL2753)
Cellosaurus ID CVCL_1D42

References: 8 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.

Thrane et al. 2014. Oncogene. PMID: 25362855.

Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.

Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.

Millour et al. 2010. Oncogene. 29(20):2983-95. PMID: 20208560.

Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.

Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-61. PMID: 16954434.


Add a reference

References: 8 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.

Thrane et al. 2014. Oncogene. PMID: 25362855.

Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.

Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.

Millour et al. 2010. Oncogene. 29(20):2983-95. PMID: 20208560.

Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.

Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-61. PMID: 16954434.


Add a reference

References: 8 entries

Joshi et al. 2016. Oncotarget. :. PMID: 27528030.

Elias et al. 2015. Oncogene. 34(15):1919-27. PMID: 24882577.

Thrane et al. 2014. Oncogene. PMID: 25362855.

Thrane et al. 2013. Breast Cancer Res Treat. 139(1):71-80. PMID: 23609470.

Cutrupi et al. 2012. Oncogene. 31(40):4353-61. PMID: 22249258.

Millour et al. 2010. Oncogene. 29(20):2983-95. PMID: 20208560.

Pancholi et al. 2008. Endocr Relat Cancer. 15(4):985-1002. PMID: 18824559.

Sarwar et al. 2006. Endocr Relat Cancer. 13(3):851-61. PMID: 16954434.


Add a reference


This reagent does not have any reviews at the moment.